Arxxant Approval Status
FDA Approved: No
Brand name: Arxxant
Generic name: ruboxistaurin mesylate
Company: Eli Lilly and Company
Treatment for: Diabetic Retinopathy
Arxxant (ruboxistaurin mesylate) is an investigational specific protein kinase C beta (PKC beta) inhibitor for the treatment of diabetic retinopathy.
In August 2006, Lilly announced the receipt of an Approvable Letter from the from the U.S. Food and Drug Administration (FDA), advising the company that it will require efficacy data from an additional Phase 3 study before it will consider approving the molecule.
Development Status and FDA Approval Process for Arxxant
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.